透明質酸鈉產品市場 - 副產品（外用、注射）、應用（藥品 [皮膚科、眼科、骨科、泌尿科]、化妝品）、最終用途（醫院、ASC） - 全球預測 2024 - 2032 年

在全球人口快速老化的推動下，基於透明質酸鈉的產品市場規模預計在 2024 年至 2032 年間複合年成長率為 7.8%。近年來，由於透明質酸鈉具有保濕和潤滑特性，對老化皮膚有益，因此對含有透明質酸鈉的眼藥水的需求顯著成長。此外，骨關節炎等關節疾病的盛行率不斷上升，促使人們偏好基於透明質酸鈉的關節內注射，以緩解疼痛並改善關節活動。美國疾病管制與預防中心(CDC) 表示，到2023 年，美國將有超過3,250 萬名成年人患有骨關節炎(OA)。的7%。

此外，消費者越來越意識到透明質酸在護膚和醫療方面的好處。由於對年輕肌膚的渴望和非侵入性抗衰老解決方案的出現，化妝品行業對基於透明質酸鈉的真皮填充劑和外用護膚產品的需求正在激增。對微創治療的日益重視以及護膚品中對天然成分的偏好將進一步推動該行業的成長。

透明質酸鈉產品產業分為產品、應用、最終用途和地區。

從應用來看，2024 年至 2032 年間，眼科領域的市場規模將達到 7.7% 的成長率。透明質酸鈉具有保持水分和提供潤滑的能力，在眼科製劑（包括人工淚液和眼內溶液）中越來越受到重視。此外，眼部藥物輸送系統的進步和對微創治療的需求不斷成長進一步推動了產品的採用。

就最終用途而言，門診手術中心領域的透明質酸鈉產品市場在 2024 年至 2032 年期間將達到 8% 的成長率。由於成本效益和住院時間減少，人們對門診手術的偏好日益增加。微創手術技術的進步也增加了以透明質酸鈉為基礎的產品在眼科手術、骨科介入和門診美容治療等手術中的使用。

由於促進使用安全有效的護膚品和眼科解決方案的嚴格法規，歐洲基於透明質酸鈉的產品行業規模在預測期內將實現 7.2% 的複合年成長率。此外，該地區消費者對化妝品和醫療產品中天然和永續成分的偏好正在增加。此外，製藥公司和研究機構之間的策略合作夥伴關係促進了創新配方和輸送系統的開發，以提高歐洲透明質酸鈉產品的功效和多功能性。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 提高人們對護膚和健康的認知
    • 技術進步
    • 美容手術的需求不斷成長
    • 骨科和眼科手術數量不斷增加
  • 產業陷阱與挑戰
    • 治療費用高
    • 潛在的副作用和過敏反應
• 成長潛力分析
• 監管環境
• 技術景觀
• 波特的分析
• PESTEL分析
• 報銷場景
• 未來市場趨勢

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 公司市佔率分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按產品分類，2018 年 - 2032 年

• 主要趨勢
• 可注射
• 專題
• 其他產品

第 6 章：市場估計與預測：按應用分類，2018 年 - 2032 年

• 主要趨勢
• 藥品
  • 眼科
  • 骨科
  • 皮膚科
  • 泌尿科
  • 其他藥品
• 化妝品

第 7 章：市場估計與預測：按最終用途，2018 - 2032 年

• 主要趨勢
• 醫院
• 門診手術中心
• 其他最終用戶

第 8 章：市場估計與預測：按地區分類，2018 年 - 2032 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 9 章：公司簡介

• ASHLAND INC.
• Allergan, Inc.
• Anika Therapeutics, Inc
• Bohus BioTech AB
• Cadila Pharmaceuticals
• Ferring B.V.
• Fidia Farmaceutici S.p.A.
• GALDERMA
• LG Chem, Ltd.
• Syner-Med (Pharmaceutical Products) Ltd.
• Zimmer Biomet

Sodium Hyaluronate-based Products Market size is set to observe 7.8% CAGR between 2024 and 2032, driven by the rapidly aging population worldwide. Of late, the demand for ophthalmic solutions containing sodium hyaluronate due to its moisturizing and lubricating properties, which are beneficial for aging skin is significantly growing. Additionally, the rising prevalence of joint disorders, such as osteoarthritis has spurred the preference for sodium hyaluronate-based intra-articular injections to provide pain relief and improve joint mobility. The Centers for Disease Control and Prevention (CDC) stated that over 32.5 million adults in the U.S. lived with osteoarthritis (OA) in 2023. Globally, OA affected more than 500 million people, which accounts 7% of the world's population.

Moreover, there is an increasing awareness among consumers about the benefits of hyaluronic acid in skincare and medical treatments. The cosmetic industry is experiencing a surge in demand for sodium hyaluronate-based dermal fillers and topical skincare products, driven by the desire for youthful-looking skin and the availability of non-invasive anti-aging solutions. The growing emphasis on minimally invasive treatments and the preference for natural ingredients in skincare products will further propel the industry growth.

The sodium hyaluronate -based products industry is divided into product, application, end-use and region.

By application, the market size from the ophthalmology segment will record a 7.7% growth rate between 2024 and 2032. The increasing prevalence of eye disorders, such as dry eye syndrome and cataracts is necessitating effective solutions for lubrication and hydration. Sodium hyaluronate, with its ability to retain moisture and provide lubrication is gaining prominence in ophthalmic formulations, including artificial tears and intraocular solutions. Moreover, advancements in ocular drug delivery systems and the rising demand for minimally invasive treatments are further driving the product adoption.

With respect to end-use, the sodium hyaluronate-based products market from the ambulatory surgical centers segment will witness 8% growth rate throughout 2024-2032. There is a rising preference for outpatient surgical procedures, driven by cost-effectiveness and reduced hospital stays. Advancements in minimally invasive surgical techniques have also increased the use of sodium hyaluronate-based products for procedures like ophthalmic surgeries, orthopedic interventions, and aesthetic treatments performed in ambulatory settings.

Europe sodium hyaluronate -based products industry size will witness 7.2% CAGR during the forecast period, attributed to stringent regulations for promoting the use of safe and effective skincare and ophthalmic solutions. Additionally, the consumer preference for natural and sustainable ingredients in cosmetic and medical products is increasing across the region. Moreover, strategic partnerships between pharmaceutical companies and research institutions have led to the development of innovative formulations and delivery systems for enhancing the efficacy and versatility of sodium hyaluronate-based products in Europe.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast calculations
• 1.5 Data sources
  • 1.5.1 Primary
  • 1.5.2 Secondary
    • 1.5.2.1 Paid sources
    • 1.5.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing awareness about skincare and wellness
    • 3.2.1.2 Technological advancements
    • 3.2.1.3 Growing demand for aesthetic procedures
    • 3.2.1.4 Rising number of orthopedic and ophthalmic surgeries
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Potential side effects and allergic reactions
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis
• 3.8 Reimbursement scenario
• 3.9 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Injectable
• 5.3 Topical
• 5.4 Other products

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Pharmaceuticals
  • 6.2.1 Ophthalmology
  • 6.2.2 Orthopedic
  • 6.2.3 Dermatology
  • 6.2.4 Urology
  • 6.2.5 Other pharmaceuticals
• 6.3 Cosmetics

Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Ambulatory surgical centers
• 7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 ASHLAND INC.
• 9.2 Allergan, Inc.
• 9.3 Anika Therapeutics, Inc
• 9.4 Bohus BioTech AB
• 9.5 Cadila Pharmaceuticals
• 9.6 Ferring B.V.
• 9.7 Fidia Farmaceutici S.p.A.
• 9.8 GALDERMA
• 9.9 LG Chem, Ltd.
• 9.10 Syner-Med (Pharmaceutical Products) Ltd.
• 9.11 Zimmer Biomet